AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

NORTH CHICAGO, Ill., Sept. 6, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Shares of AbbVie Inc. ABBV inched 0.35% higher to $193.62 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 ...

One of the world's top biopharma companies, AbbVie (NYSE: ABBV) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection. However, the shares look pricey at the moment. AbbVie is known as ...

UnitedHealth Group's Optum Rx will take AbbVie's former blockbuster rheumatoid arthritis drug off some of its lists of preferred drugs as of Jan. 1, instead favoring biosimilars that have come on ...

Sept 10 (Reuters) - UnitedHealth Group (UNH.N), opens new tab said on Tuesday it will remove AbbVie’s (ABBV.N), opens new tab blockbuster rheumatoid arthritis drug Humira from some of its lists ...